Company / Free Cash Flow
Ventyx Biosciences, Inc. Free Cash Flow History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$131.1M
FY2024
5-year range
-$167.0M / -$38.9M
FY2021-FY2024
Trend
+21.5%
vs FY2023
Sector context
#126 of 195
Health Care
What the data says
At -$131M, Ventyx Biosciences, Inc.'s free cash flow ranks #126 of 195 in the Health Care sector. Free Cash Flow returned to growth in FY2024 after 2 years of decline, reaching -$131M.
Based on SEC 10-K filings.
-$131M in FY2024.
Declined from -$99M to -$131M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#126 of 195 in Health CareTop 65% of 195This company -$131.1M Sector average $465.6M
▼
-128.2% below sector average
Key checks
Key Insights
- In FY2024, free cash flow increased 21.5% year-over-year.
- Ranks #126 out of 195 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.63 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$131.1M | +21.5% |
| FY2023 | -$167.0M | -68.6% |
| FY2022 | -$99.0M | -154.5% |
| FY2021 | -$38.9M | - |
| FY2020 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026